Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada

Published: April 23, 2020
Category: Bibliography
Authors: Aniket Bankar, Craig C. Earle, Haoyu Zhao, Javaid Iqbal, Lee Mozessohn, Matthew C. Cheung, Ruth Coxford, Vikas Gupta
Countries: Canada
Language: English
Types: Finance/Budgeting, Population Health, Utilization
Settings: Government


Health resource utilization (HRU) and associated factors of high cost are not well understood in myeloproliferative neoplasms (MPNs).


In this population-based, retrospective matched-cohort study, we used administrative health databases of Ontario, Canada to measure treatment costs and HRU for patients with MPN from 2004 to 2016 and compared them to matched controls.


In 7130 patients with MPN [essential thrombocythemia (ET) = 3481; polycythemia vera (PV) = 2618; myelofibrosis (MF) = 1031], the mean annualized treatment costs were $16,646 for ET (controls, $7070); $16,360 for PV (controls, $7293); and $25,863 for MF (controls, $7386).


Out of the total costs, the largest expenditure was on acute hospital care (ET: 57%, PV: 57%, MF: 66%). Older age (≥65), male gender, patients not seen by a specialist, and greater comorbidity burden were independent predictors of higher costs (p < 0.05). In addition, history of venous thrombosis in patients with ET and PV was associated with significantly higher treatment costs (p < 0.05).

myeloproliferative disorders,neoplasia health,resource utilization,predictors of treatment costs,population-based study

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top